The nano-enhanced antibiotic effectively erradicates bacteria from lung cells (bottom line).
Novel nanotech improves cystic fibrosis antibiotic by 100,000-fold
World-first nanotechnology developed by the University of South Australia could change the lives of thousands of people living with cystic fibrosis (CF) as groundbreaking research shows it can improve the effectiveness of the CF antibiotic Tobramycin, increasing its efficacy by up to 100,000-fold.
The new technology uses a biomimetic nanostructured material to augment Tobramycin – the antibiotic prescribed to treat chronic Pseudomonas aeruginosa lung infections in severe cases of CF – eradicating the infection in as little as two doses.
In Australia, cystic fibrosis (CF) affects one in 2500 babies – or one baby born every four days – causing severe impairments to a person’s lungs, airways and digestive system, trapping bacteria and leading to recurrent infections. Lung failure is the major cause of death for people with CF.
The UniSA research team, which includes Professor Clive Prestidge, Dr Nicky Thomas, and PhD candidate, Chelsea Thorn, says the discovery could transform the lives of people living with CF.
“CF is a progressive, genetic disease that causes persistent, chronic lung infections and limits a person’s ability to breathe,” Thorn says.
“The disease causes thick, sticky mucus to clog a person’s airways, attracting germs and bacteria, such as Pseudomonas aeruginosa, which leads to recurring infections and blockages.
“Tobramycin is commonly used to treat these infections but increasingly antibiotics are failing to make any significant difference to lung infections, leaving sufferers requiring life-long antibiotic therapy administered every month.
“Our research successfully treats advanced human cell culture lung infections using nano-enhanced Tobramycin and shows how it can eradicate serious and persistent infections after only two doses.
“This could be a real game-changer for people living with CF.”
Researchers enhanced the Tobramycin with a biometric, nanostructured, lipid liquid crystal nanoparticle (LCNP)-based material, testing it on a new lung infection model to showcase its unique ability to penetrate the dense surface of the bacteria and kill the infection.
Dr Nicky Thomas, who is supported by a Mid-Career Fellowship from The Hospital Research Foundation Group, says the discovery continues the global battle to eradicate and prevent Pseudomonas aeruginosa.
Tobramycin works by inhibiting the synthesis of bacteria and causing cell membrane damage. Yet, as it’s a concentration-dependent antibiotic, achieving a sufficiently high concentration is critical,” Dr Thomas says.
“Our technology improves the performance of Tobramycin without increasing the toxicity of the drug, so what we’re doing is a far more effective and efficient treatment for chronic lung infections.”
The technology is currently entering pre-clinical trials and hopes to be on the market in the next five years.
Original Article: Novel nanotech improves cystic fibrosis antibiotic by 100,000-fold
More from: University of South Australia
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Nano-enhanced Tobramycin
- Best Nano Cap Stocks Right Now
Investors who are looking for higher risk and more potential profit often turn to nano-cap stock options. A nano cap stock is a stock with a total market capitalization below $50 million.
- Nano Organism
All the Latest Game Footage and Images from Nano Organism Hopefully, these pen-shaped tools are easier to keep track of than AirPods… Nano Organism - is a real-time strategy game, you control ...
- How Does Tobramycin Work?
Tobramycin is an antibiotic medicine that is used to treat bacterial infections of the eye (e.g., conjunctivitis) and the eyelids (e.g., blepharitis). It may also help to prevent an infection ...
- PS5 Pro could have ‘Enhanced’ label for games that use its full power
PlayStation 4 Pro owners will remember that games with improvements to take advantage of the superior hardware would come with a “PS4 Pro Enhanced” badge on the box. This would indicate higher ...
- Tata Nano
The dashboard of the Nano GenX is the one that we first saw in the Nano Twist. It gets different colour combinations for different trims and looks way better than the old model. The centre console ...
Go deeper with Google Headlines on:
Nano-enhanced Tobramycin
[google_news title=”” keyword=”nano-enhanced Tobramycin” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Nano-enhanced drugs
- Inflammatory Bowel Diseases (IBD) Drugs Market Is Projected To Grow At A CAGR 6.2% By 2034: Visiongain
Visiongain has published a new report entitled Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034 : Forecas ...
- Nanotechnology Drug Delivery Market To Reach USD 407.8 Billion By 2032 | DataHorizzon Research
The nanotechnology drug delivery market size was valued at USD 200.6 Billion in 2023 and is expected to reach USD 407.8 Billion by 2032 at a CAGR of 8.2%.Fort Collins, Colorado (GLOBE NEWSWIRE) -- ...
- Nanomaterials Market Surge: Electronics Sector Fueling Growth with Enhanced Surface Area and Superparamagnetic Properties
The global nanomaterials market share is anticipated to attain a valuation of US$ 12.6 Billion in 2023 and is expected to reach US$ 51.5 Billion by 2033, trailing a CAGR of 15.1% during the forecast ...
- Enhancing hypoxia-activated prodrug anticancer therapy
Hypoxia-activated prodrugs (HAPs) have the potential to activate specifically in hypoxic tumors and eliminate tumor cells, which has brought new opportunities for safe and effective anticancer therapy ...
- Nano-X Imaging Ltd. (NASDAQ:NNOX) Q4 2023 Earnings Call Transcript
Q4 2023 Earnings Call April 1, 2024 Nano-X Imaging Ltd. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank ...
Go deeper with Google Headlines on:
Nano-enhanced drugs
[google_news title=”” keyword=”nano-enhanced drugs” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]